Pharmaceutical composition for treating skin diseases and method for preparing it

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and concerns a combined pharmaceutical composition for treating skin diseases. The composition contains betamethasone, preferentially betamethasone dipropionate, urea and at least one adjuvant. As adjuvants, the composition contains a hydrophobic component, an emulsifier, a preserving agent, a buffer agent, a non-aqueous solvent and water. A method for preparing the declared composition consists in the fact that the melted hydrophobic component, emulsifier and water are emulsified, and then betamethasone and the preserving agent are introduced at temperature below 60°C, homogenised and added with a prepared solution of urea and the buffer agent.

EFFECT: pharmaceutical composition is characterised by high pharmacological activity, stability, uniform distribution of the active ingredients.

7 cl, 8 ex, 1 tbl

 

The invention relates to the field of medicine and pharmaceutics, specifically, relates to compositions in the form of a cream for external use, which contains as active ingredient betamethasone and urea and is intended for external use in the treatment of dermatoses with disorders of keratinization: atopic dermatitis, diffuse neurodermatitis, simple chronic lichen (limited atopic eczema), seborrheic dermatitis, krupnoblyashechny psoriasis in the stationary phase, psoriasis of the scalp, cornea, eczema, ichthyosis and other

Treatment of dermatoses of special importance in connection with the increase in their frequency, including among children, as well as in connection with the increased frequency of severe, often torpid and treatment-resistant forms of these diseases, as well as complicated by infection. The incidence of allergic is 6-15%, psoriasis - 2-4% of the world population that determines the urgency of the problem and socio-economic importance.

The problem of therapy of dermatoses with impaired keratinization refers to a complex and important in modern dermatology. In the General structure of skin diseases share psoriatic disease reaches about 9%among hospitalized in dermatological hospitals - 35-38% [Peculiarities of clinical manifestations and course of psoriasis is a disease depending on the age of patients / Bratus-Sukhorukova EJ, Pogrebnyak L.A., Flat L.M., Tarnavsky NN. // Dermatology, cosmetology, sexual pathology. - 1999. No. 2. - 74-76], and seborrhea is the most common skin disease, its frequency of symptoms in persons from 10 to 25 years, even according to estimates most critical authors does not fall below 85%.

For the external treatment of patients with psoriasis, atopic dermatitis, dermatitis with hyperkeratosis shown drugs having, on the one hand, keratolytic and keratoplasticheskie properties, because the morphological nature of psoriasis, first of all, are hyperproliferative cells of the epidermis and the violation of keratinization. For the correction of disorders of keratinization with psoriasis and other dermatoses with impaired keratinization traditionally used drugs, containing keratolytic, in particular, salicylic acid [Dermatology. Atlas-guide / T. Fitzpatrick, R. Johnson, K. Wolff, M. Palano, da Surmang. M: PRACTICE, 1999. -1088]. On the other hand, preparations for external treatment of dermatoses with impaired keratinization must have antipruritic, anti-inflammatory and antiproliferative action. With this purpose, the most commonly used external treatment with glucocorticosteroids (GCS).

Known compositions based on one of the most effective corticosteroids, betamethasone. For example, PR is parathas Diprosalik ointment (firm "Schermg-Plough Labo N.V., Belgium) contains 0,064% betamethasone dipropionate and 3% salicylic acid in vaseline hydrophobic basis [Register of medicines Russia: radar encyclopedia of medicine. - 15th edition. CH. edit GL the vishkovsky. - M.: "radar-2007", 2006]. One of the major drawbacks of this composition, as 2-10% ointment of salicylic acid is that it is prepared only on hydrophobic vaseline basis, which disrupts thermoregulation breathing of the skin, and therefore unsuitable for use on large areas of affected skin for a long period. Such external means extremely inconvenient for outpatient use, as it stain clothes, their use requires disturbing the normal rhythm of life for a period of drug application and subsequent thorough rinsing. Hydrophobic base also makes them unsuitable for use on the scalp, especially in the outpatient setting for the treatment of patients with exudative forms of psoriasis, pustular psoriasis, etc.

In this regard, practical medicine requires drugs with the same complex action, but containing hydrophilic excipients. The number of known drugs on this basis, containing betamethasone, for example, the composition according to the patent of Russian Federation №2225208 or drug Beloderm cream (Belupo, Croatia), which is almost equivalent to therapeutic effectiveness. Drug Beloderm contains betamethasone dipropionate and excipients.

Known combined creams containing corticosteroid in combination with urea. This medication Hydrogenin cream (Roch Pharma)containing 1% hydrocortisone and 10% urea, and Prednicen cream (CJSC "Pharmaceutical company "Darnitsa")containing 0.5% prednisolone and 10% urea [COMPENDIUM 2008 - medications: In two volumes / Ed. by V.N. Kovalenko, A.P. Viktorova. - K.: MORION, 2008. - 2270,49; Rote Liste, 2000]. However, these preparations contain a weak GKS and inefficient for the external treatment of dermatoses.

It is also known that urea can form with many water-insoluble substances clathrate compounds (connection connection) due to the inclusion of these substances in the cavity associates, formed by molecules of urea [Sweetman SC (Ed), Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Electronic version, (2007)], which significantly complicates the development of pharmaceutical preparations containing urea.

Thus is still relevant to the development of a drug based on a combination of glucocorticosteroid with keratolytically for the treatment of inflammatory and allergic diseases, including proceeding with a violation of the process of keratinization of the skin: subacute and chronic giperkineticeskih and dry dermatoses, such as psoriasis, atopic dermati is, flat lichen, eczema (including coins eczema, hand eczema, eczematous dermatitis, dyshidrosis, seborrheic dermatitis, common ichthyosis and other ihtiosiformnye medicine.

The objective of this invention is to provide a new pharmaceutical composition for external use in the form of a cream with the best combination of auxiliary substances containing a combination of strong corticosteroids and urea, and intended for cutaneous treatment of dermatoses with disorders of keratinization, and to develop a method of producing such a composition.

To solve this problem is proposed pharmaceutical composition in the form of soft medicinal forms for the treatment of skin diseases, which includes betamethasone dipropionate, a urea, a hydrophobic component, an emulsifier, a preservative, a buffering agent, a non-aqueous solvent and water, the content of betamethasone dipropionate is 0.01-0.1 g/100 g of the composition and the composition has a pH from 4.5 to 7.1.

The preferred concentration of betamethasone dipropionate is 0.01-0.1 g/100 g of the composition. Preferably betamethasone dipropionate is used in the preferred concentration 0,064% or 0.05 g/100 g of the composition in terms of betamethasone.

Betamethasone dipropionate (9-fluoro-11β-hydroxy-16β-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropionate) - ftoridov the config synthetic glucocorticoid, in structure and pharmacological activity similar to dexamethasone and which is its β-isomer [Reference Vidal. Drugs in Russia: a Handbook. - M.: Estrofem Service, 2007. - 1632 S.; Mashkovsky PPM Medicines. - M.: Publishing house "New wave", 2005. - 1200 C.].

Betamethasone dipropionate is used in the claimed compositions in combination with urea, which greatly potentiates the pharmacological action of the composition (anti-inflammatory, vasoconstrictor). Urea favorably with their harmlessness, as a natural part of our body, and, in addition, exhibits an antimicrobial effect.

The presence of various pathological processes that occur in the dermis chronic dermatoses, on the one hand, and exogenous drying the influence of external factors on the skin, on the other hand, necessitates the presence in the composition of the humidifier. Urea may also perform the function of a moisturizer because it attracts from environmental water and keeps it in the stratum corneum, thereby soften the skin and improve its elasticity.

Because the local application of urea is not absorbed into the systemic circulation, any systemic side effects are excluded. The only side effect, the manifestation of which is possible if the local application of soft drugs, containing a high concentration of urea is skin irritation. The preferred concentration of urea is 3-20 g/100 g of the composition, more preferably from 5 to 12 g/100 g of the composition

The claimed composition is intended for cutaneous use and provision of local action. A comparative study of the acute and chronic toxicity, irritant action and immunotoxicity. In addition, compared with the prototypical drug Beloderm cream (Belupo, Croatia) investigated specific pharmacological (anti-inflammatory and vasoconstrictor) activity.

It is established that at dextranomer exudative edema double application of the claimed composition (betamethasone dipropionate and urea) and of the reference preparation in a total dose of 200 mg cream/rat (=0.36 mg/kg) betamethasone) have a growing anti-inflammatory effect. The effect of the proposed drug within 1 hour after application is 33.6%, slightly increasing to 3 hour up to 43%. The effect of the drug Beloderm cream is less pronounced and is 1 hour of 22.2%, remaining at the same level up to 3 hours (24,4%). The total effect of the new composition, calculated as area under the curve "time-effect", accounted for 93.4, which is 1.6 times more of this indicator for the comparison drug (57,7).

When Aerosila Aksu is exploring the swelling anti-inflammatory effect of the proposed drug in the same dose was 1 hour after induction of inflammation 36,1%, to 5 a.m. - 40,9%, to 24 hour - by 16.7%. The effect of the drug Beloderm cream after 1 h corresponds to that in the case of the claimed composition, accounting for 36.7 per cent, declining further: to 5 hours to 28.4%, to 24 hour to 3.1%. Total anti-inflammatory effect of the claimed composition was 719,3 that also 1.6 times higher than that of drug Beloderm cream 447,8.

In a single cutaneous application of the authors on intact skin at a dose of 100 mg/person vasoconstrictor effect of the proposed composition and preparation Beloderm cream in 15 minutes after application respectively 43,6% and 45.5%. By the 30 minute activity of a new drug is reduced by a factor of 1.2 (up to 37,2%), whereas the effect of the drug Beloderm cream decreases faster - 1.7 times (to 26.3%).

In General, the results of a comparative study of specific pharmacological activity of drugs allow us to conclude that the compared drugs have a characteristic anti-inflammatory and vasoconstrictor activity. However, the inventive composition is characterized by a higher activity, which is explained by the synergistic action of urea on the pharmacologic effect of betamethasone.

The results of studies of acute toxicity indicate that the inventive composition is practically non-toxic substances. Application of the drug at a dose of 1.50 g/kg on the Xu the surface of the animal body, except for head and tail, death is not caused. According to the clinical symptoms of intoxication of animals and the level of acute toxicity of a new drug with drug comparison of Beloderm cream.

Obtained in the chronic experiment results indicate that cutaneous application of the inventive composition to rats for 1 month in doses 0,150 g/kg (1/10 of the maximum tested in acute experiments) has no toxic effect on the General condition of the animals, functional characteristics of the Central nervous system, the electrophysiological activity of the myocardium, peripheral blood, does not cause pathological changes of basic biochemical parameters of blood of animals that characterize the metabolic processes in the liver, kidney, myocardium.

The results of pathological studies indicate that for cutaneous application within 1 month in the studied doses, we offer the drug does not change, such factors as the relative weight of internal organs of rats. After exposure to the drug is not detected morphological features cardiotoxic, nephrotoxic and hepatotoxic effect on the organism of experimental animals. The claimed composition does not show local irritating action on the skin, which is confirmed histologically.

Research results immunodeficiency is otoxicity showed that skin application of the inventive compositions within 14 days at a dose of 0.133 g/kg (1/10 of the maximum dose studied in acute experiments in terms mice) do not cause significant changes in rates of cellular and humoral immune system in mice.

The results obtained in the chronic experiment, show that the parameters of the toxicity of the composition according to the invention corresponds to the comparison drug.

As auxiliary substances, the composition also contains a hydrophobic component, emulsifier, preservative, hydrophilic component (a buffering agent, a non-aqueous solvent and water). The preferred contents of the ingredients of the composition is, g/100 g composition:

Betamethasone dipropionate -of 0.01-0.1
Urea3-20
The hydrophilic component34,0-90,5.
Hydrophobic component5,0-25,0
Preservativeof 0.01 to 3.0
Emulsifier5,0-12,0,

and the composition has a pH of 4.5 to 7.1

As gidrofobnogo the component can be used vaseline, liquid paraffin, squalane, isopropylmyristate, isopropyl, octyldodecanol, cyclomethicone and Dimethicone. It is preferable to use a combination of vaseline, vaseline oil and squalane concentration % (g/100 g of composition):

Vaseline5-9
Vaseline oil5-9
Squalene2-5

Such excipients hydrophobic phase with different fluidity provides good amazement on the skin

As the emulsifier can be used in combination of nonionic emulsifiers of the 1st and 2nd kind from among ethoxylated alcohols fatty acids; esters of sorbitol and fatty acids; mixtures of mono - and diesters of diethylene glycol or glycerin fatty acid, ethoxylated derivatives of glucose. It is preferable to use a combination of emulsifiers of macrogol 20 cetosteatil ether (emulsifier 1 St kind) and cetosteatil alcohol (emulsifier 2nd kind) concentration (g/100 g of composition):

Of macrogol 20 cetosteatil ether2-3
Cetosteatil alcohol5-8

As preservative can be used in different types of parabens, preservatives-based Phenoxyethanol, midmotion. Preferably the use of methylparaben (nipagina) at a concentration of 0.1-0.3 (g/100 g of composition).

Hydrophilic substance selected from the group comprising water, non-aqueous solvent and a buffer substance. Preferably the hydrophilic substance is a combination of non-aqueous solvent and water, or a combination of water, non-aqueous solvent and a buffer substance.

As the nonaqueous solvent can be used propylene glycol, glycerin, PEO-400, hexyleneglycol, diethylene glycol monotropy ether. Preferably the propylene glycol at a concentration of 3-7 (g/100 g of composition).

The original aqueous urea solutions have a neutral pH environment. However, during storage the pH is increased to 8.0 to 8.5. This is due to the characteristic of urea property - the ability of urea to either hydrolyzed in aqueous solutions with the formation of carbon dioxide and ammonia, which inevitably leads to an increase in pH [Nayland OA Organic chemistry: Textbook. for chem. spec. higher education institutions. - M.: Higher school, 1990. - 751]: Therefore, in the preferred embodiment of the invention, the inventive composition comprises a buffering agent.

Preferably as Boo the cluster substances used substance, providing the pH of the cream is in the range from 4.5 to 7.1. As buffer substances can be salts of phosphoric, acetic, phthalic, citric, lactic acids, lactones, amino acids and their salts. Preference is given to the use of the buffer mixture, based on the organic buffer substances, mainly DL-pantolactone and arginine at a concentration of % (g/100 g of cream)

DL-pantolactoneof 0.5-3.5
Arginine0,02-0,2

For example, when using organic buffer substances DL-pantolactone and arginine cream containing 10% urea and 2.3% DL-pantolactone, the source has a pH of 3.43. When stored for 9 months pH of the cream reaches 6,23. With the introduction of arginine in creams containing 10% urea and 2.3% DL-pantolactone, their pH is increased; when the pH is higher, the higher the concentration of arginine (at a constant concentration of DL-pantolactone). At low concentrations of arginine pH creams during storage increases the more, the lower the concentration of arginine. Since the concentration of arginine 0,075%, pH creams stabilized and stored for 9 months remains approximately at the same level. Thus, DL-pantolactone and arginine form the buffer mixture in solutions of urea is stabilize pH, apparently, preventing the hydrolysis of urea during storage. By varying the ratio between the components of the buffer mixture, it is possible to control the pH of the cream.

Studies have been conducted to study the stability of betamethasone dipropionate. For these studies were developed formulations with a pH from 4.5 to 7.5; pH regulate the content of buffer substances. The concentration of betamethasone and its impurities in the cream was determined by HPLC method.

Source after manufacture of the drug impurities formed in the sample, which had an alkaline environment (pH 7.5). The sum of the peak areas of the impurities relative to the peak area of betamethasone dipropionate was 8,17%.

At a pH of from 7.0 to 4.5 impurities in the manufacturing process of the drug are not formed. After storage for 3 months at 40°C, which corresponds to approximately 1 year of storage at 25°C, changed the pH of the samples. The sample with initial pH of 7.5, the pH was raised to 9.5, the environment has become more alkaline, which is caused, apparently, by hydrolysis of urea. The sample with initial pH of 4.5 has been a decrease in pH up to 4.01. Samples with a pH from 7.0 to 5.0 pH approached 6,0.

In the sample composition No. 1, which had an alkaline pH environment, the impurities are increased from 8.17% to 13.40%. On the chromatograms of samples No. 2-7 after storage appeared peaks of impurities with a retention time less than the retention time of betamethasone dipropionate is a, however, the content of these impurities is negligible.

It should be noted that approximately the same level of impurities (an increase from 0.1% to 0.7%) is observed for the experimental series of the drug accumulated in the reactor-homogenizer and stored at 25°C for 2 years. During the retention period, the pH of these creams remained approximately 6.0.

Preferably offer therapeutic composition is made in the form of a cream and is a complex emulsion of the dispersed system. The inventive composition is characterized by a homogeneous distribution and a minimum particle size of the hydrophobic phase of the emulsion. The size of the particles of the oil phase of the cream is not more than 15-20 microns, and a bulk to 10 microns.

The choice of ingredients and their ratio significantly affects the way of obtaining drugs. According to the proposed method perform emulsification of hydrophobic melt phase, emulsifier and water, and then injected with betamethasone dipropionate and preservative in the form of a solution or in suspension at a temperature below 60°C, preferably in the form of a solution, homogenized and injected previously prepared solution of urea. In a preferred embodiment, the urea is injected together with a buffer substance.

The distinguishing features of the claimed method of obtaining a composition having Auda:

- introduction of betamethasone dipropionate and preservative in the finished emulsion at a temperature below 60°C, which on the one hand retains a liquid consistency basics and allows active substances to quickly spread across all of the volume, but on the other hand reduces the time of exposure to high temperature on the active components.

- introduction of the urea solution at the lowest possible temperature before thickening cream that provides a uniform distribution, the lack of hydrolysis of urea and subsequent rapid cooling of the cream.

The result is the most uniform distribution of active ingredients in the finished form, which is essential for medicines. Change the boot order and temperature regimes, namely the introduction of active substances at the initial stage at the time of emulsification or after structure formation (thickening) of the cream may cause non-uniform distribution of active ingredients in volume and volatility of the composition and active ingredients during storage.

The following examples illustrate the invention. A typical example (example 1). In a laboratory reactor equipped with a stirrer, a homogenizer and a thermometer, load sequentially purified water, the mixture of vaseline, vaseline oil and squalane (in the ratio 2:2:1, hydrof BNY component), a mixture of macrogol 20 cetosteatil ether and cetosteatil alcohol in equal proportions (emulsifier). The mass is heated to 70°C, can withstand up to full melting of the components and homogenized with vigorous stirring at a temperature of 70-75°C for 10 min, then gradually cool the cream at medium speed stirring to 55°C. Separately prepared solution of methylparaben (preservative) and betamethasone dipropionate in a heated up to 60°C propylene glycol (nonaqueous solvent), add the resulting solution to a cream Foundation with a temperature of 55°C, homogenize the mass within 5-10 minutes Cool down a lot at medium speed stirring to 45°C and load the previously prepared aqueous solution of urea and the solution pantolactone (buffering agent). The resulting solution was loaded into the reactor at a temperature of 45°C and homogenize for 5 minutes a Homogeneous mass is gradually cooled down to 25-27°C and Packed in tubes.

Similarly obtained examples 2-8 (table), with the difference that as the hydrophobic component were used isopropylmyristate (example 2), paraffin wax and liquid paraffin (example 3), octyldodecanol (example 4), isopropyl (example 5), isopropylmyristate and cyclomethicone (example 7) and isopropylmyristate, squalane and Dimethicone (example 8); as preservative propylparaben (example 3), EuxlPE9010 (Phenoxyethanol 90%, Ethylhexylglycerin 10%, example 5), imagemotion (example 6), sodium benzoate (example 7), a mixture of methyl and propyl parabens in the ratio 2 : 1 (example 8); as hydrophilic nonaqueous solvent butyleneglycol (example 2), hexyleneglycol (example 4), polyethylene oxide 400 (example 5), glycerin (example 6), diethylene glycol monotropy ester (example 7) and Dimexidum (example 8); as emulsifier monocationic ether of polyethylene glycol (example 2), cetosteatil alcohol (example 3), emulsifying wax (examples of 4.7), emulsifier Lanette (a mixture of high molecular weight alcohols with the number of carbon atoms from 14 to 20, mainly cetyl and stearic, and, optionally, sodium alkyl sulphates, mainly nutriceuticals and netresearchserver, example 5), emulsifier Cremophor (macrogol-glycerylhydrostearate example 6), emulsifier No. 1 (mixture of primary higher fatty alcohols with a number of carbon atoms of 16 to 20 and sodium salts of sulfonic ethers of such alcohols, example 8); as a buffer substance pantolactone and arginine at a ratio of 1.5 to 1 (example 2), nitrate buffer (citric acid/sodium citrate, example 3), lactate buffer (example 5), malic acid and sodium hydroxide (example 6), phosphate buffer (example 8)

Table
The Ingram is anti Content, g/100 g of the composition
1234
Betamethasone (calculated on the basis of betamethasone)0,010,020,050,07
Urea381012
Hydrophobic component
Preservative1,00,40,20,2
Nonaqueous solvent2456
Emulsifier57912
The buffer substanceto pH of 7.1to pH 5.0to pH 4.5to pH 6,0
Water100100100100
IngredientsContent, g/100 g of the composition
5678
Betamethasone (calculated on the basis of betamethasone)0,10,030,050,05
Hydrophobic component
Urea207129
Preservative0,050,10,10,1
Nonaqueous solvent10456
Emulsifier106810
The buffer substanceto pH 5,5to pH 5.0to a pH of 6.5to pH 6,0
Water100100100100

1. Pharmaceutical what I composition in the form of soft medicinal forms for the treatment of skin diseases, which includes betamethasone dipropionate, a urea, a hydrophobic component, an emulsifier, a preservative, a buffering agent, a non-aqueous solvent and water, the content of betamethasone dipropionate is 0.01-0.1 g/100 g of the composition and the composition has a pH from 4.5 to 7.1.

2. The pharmaceutical composition according to claim 1, characterized in that the urea concentration is 3.0 to 20.0 g/100 g of composition.

3. The pharmaceutical composition according to claim 1 or 2, characterized in that it contains as a non-aqueous solvent is propylene glycol.

4. The pharmaceutical composition according to claim 3, characterized in that it contains as the hydrophobic component is a combination of petrolatum, paraffin oil and squalane.

5. A method of obtaining a composition for the treatment of skin diseases, which emuleret the hydrophobic melt component, an emulsifier and water, and then injected with betamethasone dipropionate, a preservative and a non-aqueous solvent at a temperature below 60°C, homogenized and injected previously prepared solution of urea and a buffering agent.

6. The method according to claim 5, in which the betamethasone dipropionate administered in the form of a solution.

7. The method according to claim 6, in which the urea is injected together with a buffer substance.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating guttate psoriasis. For this purpose, with underlying ointment therapy, the narrow-band medium-wave UV-radiation is applied at wave length 311 nm. That is preceded by prescribing Perfloxacin 400 mg twice a day for 5-7 days.

EFFECT: method enables reducing a number of procedures, reducing a dose of the medium-wave UV-radiation, ensuring the faster clinical effect and prolonging the remission, arresting a comorbidity, reducing a probability of side effects and complications.

2 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of dermatology and represents application of 1-aminoalkylcyclohexane derivative, selected from neramexane and its pharmaceutically acceptable salts for treatment or prevention of inflammatory skin diseases, which represent acne, irritant dermatitis, impetigo and atopic dermatitis.

EFFECT: invention ensures extension of arsenal of medications for treatment of inflammatory skin diseases.

39 cl, 7 ex, 35 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: in formula (VIII):

X represents NR7; Y represents O or N-(CH2)nR19; n is equal to 1 or 2; m is equal to 1 or 2; R1 represents H or C1-6alkyl; R2 independently represents H, C1-6alkyl or C5-6cycloalkyl; each of R4 and R4 independently represents H or C1-6alkyl; or R4 and R4 together form spiro-C3-6cycloalkyl group; R19 represents H, C1-6alkyl, C6aryl or C3cycloalkyl group; R6 represents OR8 ; and each of R7 and R8 independently represents H or C1-6alkyl. The invention also refers to compounds of formula VI, VII, a pharmaceutical composition containing said compounds, and a method of treating a proliferative disease, such as cancer.

EFFECT: invention refers to new pyrimidine derivatives and their pharmaceutically acceptable salts possessing the properties of a PLK1 kinase inhibitor.

24 cl, 8 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns an agent for neutralising toxic action of tumour necrosis factor on the basis of hydrated pyrido(4,3-b)indoles of formula (1), a pharmaceutical agent on the basis thereof, and a method of treating autoimmune diseases on the basis of neutralising toxic action of tumour necrosis factor.

EFFECT: preparing the agent for treating autoimmune diseases on the basis of neutralising toxic action of tumour necrosis factor.

13 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating psoriasis vulgaris. That is ensured by a therapy involving a combination of the hepatoprotector Phosphogliv and an external non-hormonal therapy. Phosphogliv is prescribed according to the schedule: 2.5 mg intravenously once a day for 10 days, then orally 1 capsule 3 times a day; and the non-hormonal preparation is Cinocap cream 3 times a day; the therapeutic course makes 4 weeks.

EFFECT: invention enables reducing a risk of complications and side effects and prolongs remission ensured by anti-inflammatory, hypolipidemic, immunomodulatory action of the prescribed preparations.

FIELD: medicine.

SUBSTANCE: what is presented is the use of xenon in the form of an agent for external therapy of chronic recurrent inflammatory dermatopathies prepared by extra pure grade xenon saturation of a fatty base.

EFFECT: what is shown is considerable reduction of an inflammatory reaction on the second therapeutic day in such polygenic chronic inflammatory diseases, as psoriasis, atopic dermatitis, acne, acne rosacea, eczema.

4 ex

FIELD: medicine.

SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating psoriasis vulgaris. For this purpose, a patient is exposed to narrow-band medium-wave ultraviolet (UV therapy) at wave length 311 nm. It is combined with introducing liptonorm 10 mg once a day for 21-28 days. The UV therapeutic course makes 10 procedures.

EFFECT: method provides fast and prolonged clinical remission of the disease, as well as reduced side effects of the therapy due to the specified UV exposure mode and liptonorm introduction ensuring high photosensitising effect.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to solid forms of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulphonylethyl]-4-acetylaminoisoindoline-1,3-dione of formula (I) inhibiting TNF-α or PDE4 production that enables using them in treating psoriasis.

EFFECT: producing an agent for treating psoriasis.

36 cl, 14 tbl, 33 dwg, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a pharmaceutical composition for local application containing fusidic acid within the range of 1 wt % to 5 wt % and mometasone within the range of 0.05 wt % to 2 wt % and a pharmaceutically acceptable carrier to be applied in treating or preventing inflammatory dermatoses caused by a secondary bacterial infection in a patient.

EFFECT: invention provides effective elimination of secondary bacterial infections in dermatologic injuries.

11 cl, 8 ex, 6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula (I) and its pharmaceutically acceptable salts possessing dihydroorotate dehydrogenase inhibitory ability, to a based pharmaceutical composition, to application thereof in preparing a drug compound and to a combined preparation containing the presented compounds and the other active compound (I) in effective amounts wherein both groups G1 mean CRC, G2 mean a nitrogen atom or group CRd, of the groups G3 and G4 mean a nitrogen atom and the other one means group CH, M means a hydrogen atom or a pharmaceutically acceptable cation, while R1, R2, Ra, Rb, Rc and Rd have the values specified in the patent claim.

EFFECT: preparing pharmaceutically acceptable salts possessing dihydroorotate dehydrogenase inhibitory ability.

25 cl, 115 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents an polycomponent adhesive ointment for treating erosive lesions of the oral mucosa accompanying pemphigus, containing sea buckthorn oil, and 0.5% prednisolone ointment, characterised in the fact that it further comprises dental adhesive paste 'Solcoseryl', gel 'Lidoxor' and 'Polysorb MP' in the following percentage ratio of the ingredients: sea buckthorn oil - 20, 0.5% prednisolone ointment - 20, dental adhesive paste 'Solcoseryl' - 30, gel 'Lidoxor' - 20, 'Polysorb MP' - 10.

EFFECT: invention provides the higher clinical effectiveness in erosive lesions of the oral mucosa accompanying pemphigus due to reducing the length of epithelialisation of the affected mucosa.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for local administration. The pharmaceutical composition for local administration characterised by the fact that it contains ketoconazole, or fluconazole, or terbinafine, as well as liposomes, an emulsifier, a preserving agent, demineralised water taken in certain proportions (versions).

EFFECT: composition provides fast cutaneous penetration of the active substances.

3 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to medicine and describes gel-base for external application, which includes water phase, which contains modified rarely linked acrylic polymers or based on them suspensions, subjected to electrophysical influence with electrical nonlinear-distorted signals with two intervals of homogeneity, with concentration of rarely linked acrylic polymers in hydro-gel constituting 0.2-0.6% wt, its viscosity being 45-85 Poise, and value of pH equal 7.2±0.2.

EFFECT: gel-base can additionally contain antiseptics, and/or antimicrobial components, and/or antioxidants, and/o antihypoxants, and/or anti-inflammatory components and intensifies wound healing, reduces quantity of purulent complications in their treatment, has antiseptic and anti-inflammatory effect.

21 cl, 1 ex, 3 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: claimed is application of levodopa and carbidopa for preparation of medication, intended for treatment of Parkinson's disease; or for treatment of sleep malfunction in patients with Parkinson's disease, for treatment of motive activity malfunction in patients with Parkinson's disease (versions), where medication contains levodopa and carbidopa in pharmaceutically effective quantity for continuous introduction into intestine for time period, which constitutes 24 h per day or more than one day. Sleep rating scale of patients with Parkinson's disease increased by 130% on the second night after starting twenty-four-hour introduction and remained within two following years.

EFFECT: twenty-four-hour introduction of medication replaces frequent per oral intake of medications, makes it possible to reach claimed prescriptions, with preservation of stable response to on medication introduction, which is not accompanied by development of clinically significant tolerance or side effects.

17 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to enzymatic wound healing medication. Enzymatic wound healing medication, which contains enzyme ultra-lysine in form of liquid substance, antiseptic myristamide and auxiliary substances - emuksol-268 and polyethyleneglycol, taken with specified ratio.

EFFECT: medication has increased wound healing activity.

4 dwg, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating skin diseases. The composition contains a combination of methylprednisolone aceponate and glycoceramides and a glycoceramide complex containing cholesterol in the amount of 1-3%, and phospholipids in the amount of 25-34%, and excipients. A method for preparing the composition consists in the fact that methylprednisolone aceponate is introduced into an emulsion base containing the glycoceramide complex in the form of a solution to form a coagulation structure.

EFFECT: new pharmaceutical composition is characterised by a wide spectrum of pharmacological properties, stability, uniform distribution of the active ingredients.

9 cl, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to pharmaceutical compositions for local application. Claimed compositions include sildenafil, minoxidil, testosterone, or alprostadil, euphyllin, yohimbine, or sildenafil, minoxidil, yohimbine as active agents respectively. Claimed compositions also contain hydrogenated lecithins in combination with cholesterol, emulsifying agent, preservative and demineralised water in specified weight ratios.

EFFECT: group of inventions ensures fast penetration through skin and complex therapy of erectile dysfunction taking into account impact on psychogenic and endocrine factors.

3 cl, 4 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Described is system of transdermal delivery of medication for passive transdermal delivery of one or more than one ionised active agent onto biological surface of subject. System of transdermal medication delivery includes carrying substrate and layer of active agent. Layer of active agent includes thickening agent, plasticiser and therapeutically efficient quantity of ionised active agent.

EFFECT: claimed is novel system of transdermal medication delivery for passive transdermal delivery of one or more than one ionised active agent onto biological surface of subject.

23 cl, 32 dwg, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and cosmetics, more specifically to a topical pharmaceutical composition possessing comedolytic and antibiotic action, comprising an effective amount of the antibiotic clindamycin, salicylic acid and excipients. The pharmaceutical composition is presented in the form of a gel. The excipients are as follows: acrylate copolymer emulsion Salcare SC80, allantoin, antioxidant dihydroquercetin preservative Sharomix MCI, propylene glycol, cyclomethicone DC 345, tocopherol phosphate, UV filter Escalol 567, emulsifier DC 5329, trometamol and thermal water.

EFFECT: stabilised composition has strong comedolytic and antibiotic action, comprises the protective SPF factor which protects inflamed skin against the negative effects of UV radiation and has a shelf life of at least 3 years.

3 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of veterinary medicine, namely to veterinary pharmacology. Method of obtaining medicinal ointment for animals, includes manufacturing ointment base, consisting of mixture of colophony, wax, vegetable oil and addition of active substances in form of precipitated sulphur, boric acid, 2-3% benzyl alcohol is introduced into ointment base brought to complete dissolution at t- 65-76°C with further addition of 3-4% citric acid with following mixing of components by homogenisation at t -40-50°C and filtration.

EFFECT: reduction of treatment terms is ensured.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology and radiology, and may be used for treating radiation-induced lung injuries complicated by the abscess formation. That is ensured by using anti-inflammatory agents such as corticosteroids, antibiotics, and inhalation of 10% dimethyl sulphoxide; bronchodilators, mucolytics, antiplatelet, antihistamines, antitussives, breathing exercises and oxygen therapy. In this case, the treatment is performed in hospital environment and combined with using detoxification, analgesic, hemostatic agents and antitussives, controlled hypotension, abscess cavity sanitation; the above aids are used till pain management, body temperature normalisation, general status stabilisation, cough and dyspnea relief. Then, replacement, metabolic, reparative and immune agents are prescribed additionally. The treatment is continued until the Karnovskiy functional status is stabilised at 60-80%, while decreasing the amount of the abscess cavity discharge by 50% or the absence; in this case the patient is transferred to the outpatient treatment with regular admission when the Karnovskiy status is occurred to decrease to 40-50%, while the QOLi-NS value decreases to 25 points, and an X-ray pattern seem to alternate.

EFFECT: invention provides the conservative treatment of complicated radiation-induced lung injuries; it enables prolonging the life and quality thereof in the patients suffering radiation-induced purulent-destructive chest processes.

23 cl, 6 dwg, 2 tbl, 2 ex

Up!